ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
MedDay Announces Full Patient Enrollment for MD1003 Trial
November 10, 2018
MedDay Pharmaceuticals announced full enrollment of SPI2, a phase III clinical trial designed to confirm the potential of its investigational drug MD1003 in progressive MS as shown in MS-SPI phase III trial.
Pharma Sources Insight July 2025
